Ambrisentan for Early-Stage Low-Risk Pulmonary Arterial Hypertension: Design of the Randomized, Double-Blind, Placebo-Controlled ALEPH Trial | JACC Asia
From JACC Specialty Journals by American College of Cardiology
June 2, 2026 · 1 min
About this episode
Dr. Jian'an Wang provides commentary on the design of the ALEPH trial for early-stage low-risk pulmonary arterial hypertension.
Commentary by Dr. Jian'an Wang.
People in this episode
Guest: Dr. Jian'an Wang
Topics covered
- pulmonary arterial hypertension
- clinical trial
- medical commentary
- cardiology
- healthcare
Keywords
- Ambrisentan
- pulmonary arterial hypertension
- clinical trial
- double-blind
- placebo-controlled
- JACC Asia
Mentioned in this episode
Organizations: American College of Cardiology
Books & works: ALEPH Trial
More episodes of JACC Specialty Journals
- Comparison of Flow Ratio Derived From IVUS With CAG in Complex Lesions: Correlation With FFR | JACC Asia · June 2, 2026 · 1 min
- Sex Differences in Antiarrhythmic Effects of Empagliflozin: The EMPA-ICD Trial Subanalysis | JACC Asia · June 2, 2026 · 1 min
- Association Between Cardiac Acceleration Capacity and Susceptibility to Vasovagal Syncope: Autonomic Dysregulation in Vasovagal Syncope | JACC Asia · June 2, 2026 · 0 min
- Cardio-Kidney-Metabolic Phenotypes and Adverse Clinical Outcomes in Patients With Atrial Fibrillation | JACC Asia · June 2, 2026 · 0 min
- Postoperative New-Onset Heart Block in Noncardiac Surgery: Model Development, Validation, and Long-Term Prognostic Analysis | JACC Asia · June 2, 2026 · 0 min
- The Associations Between Heart Rate, Deformational Echocardiographic Parameters, and Outcomes in Patients With Atrial Fibrillation | JACC Asia · June 2, 2026 · 1 min
Explore listener stats, chart rankings, contacts and more on the JACC Specialty Journals podcast page.